Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma Launches a New Generic Prescription Drug
Details : Blexten-Generic (bilastine) is a histamine H1 receptor inhibitor, which is indicated for the treatment of seasonal allergic rhinitis & chronic spontaneous urticaria.
Product Name : Blexten-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2024
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunshine Biopharma's Nora Pharma Receives Approval for Niopeg(R) Biosimilar
Details : Niopeg (pegfilgrastim) is an FDA-approved G-CSF agonist for treating febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.
Product Name : Niopeg
Product Type : Protein
Upfront Cash : Inapplicable
April 19, 2024
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
